AG
CLSD

Aperio Group’s Clearside Biomedical CLSD Stock Holding History

Aperio Group’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$52K Hold
1,254
– – ﹤0.01% 2409
2020
Q3 		$29K Hold
1,254
– – ﹤0.01% 2364
2020
Q2 		$35K Buy
1,254
+214
+21% +$6.3K ﹤0.01% 2310
2020
Q1 		$27K Hold
1,040
– – ﹤0.01% 2297
2019
Q4 		$45K Sell
1,040
-339
-25% -$7.12K ﹤0.01% 2304
2019
Q3 		$13K Sell
1,379
-184
-12% -$2.64K ﹤0.01% 2302
2019
Q2 		$23K Buy
1,563
+843
+117% +$15K ﹤0.01% 2672
2019
Q1 		$15K Buy
+720
New +$14.3K ﹤0.01% 2282

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Aperio Group's CLSD Position: Q4 2020 in Review

Aperio Group held its Clearside Biomedical (CLSD) position steady in Q4 2020 at 1,254 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #2409.

Aperio Group first reported a position in CLSD in Q1 2019 and has held it in 8 quarters since. 42 funds tracked by Wall St. Rank hold CLSD as of Q4 2020.

  • Aperio Group held 1,254 shares of Clearside Biomedical worth $52K as of Q4 2020.
  • Aperio Group left its Clearside Biomedical share count unchanged in Q4 2020.
  • Clearside Biomedical made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2409 holding.
  • Aperio Group first reported a position in Clearside Biomedical in Q1 2019 and has held it in 8 quarters since.
  • 42 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.